[ad_1] SHANGHAI, Nov. 29, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines,…
Tag: IgA
Everest Medicines Announces China NMPA’s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients
[ad_1] –Nefecon® is the first approved medicine with an IgAN indication in China— –The approval marks a new era of IgAN treatment for Chinese patients– SHANGHAI, Nov. 23, 2023 /PRNewswire/…
Malaysia has implemented 16 FTAs, 62 bilateral IGAs to date – Tengku Zafrul
[ad_1] KUALA LUMPUR: Malaysia has implemented 16 free trade agreements (FTAs) and 62 bilateral investment guarantee agreements (IGAs) to date, said Investment, Trade and Industry Minister Tengku Datuk Seri Zafrul…
Picchioni’s IGA in Roundup celebrates 100th anniversary
[ad_1] ROUNDUP — A visit to the grocery store is something everyone does multiple times a week but, in some places, that store is more than just a place to…
3 Months After Lavish Deal With Roger Federer’s Billion-Dollar Brand, Iga Swiatek Proves That the Swiss Star’s Influence Goes Beyond Business With an Agile Move in Germany
[ad_1] After moving away from the court in the previous season, Roger Federer ventured into the realms of business by launching his sports apparel brand, ‘On’. Since then, the Swiss…
IgA Nephropathy (IgAN) Epidemiology Forecast Report 2019-2023 & 2023-2032: Focus on 8 Major Markets – United States, Germany, Spain, Italy, France, United Kingdom, Japan, and China – ResearchAndMarkets.com
[ad_1] IgA Nephropathy (IgAN) Epidemiology Forecast Report 2019-2023 … WV News [ad_2] Source link
Everest Medicines Announces New Drug Application Acceptance by Singapore HSA for Nefecon for the Treatment of Primary IgA Nephropathy
[ad_1] Nefecon NDA is currently under Priority Review in China and expected to receive approval in 2H 2023 SHANGHAI, April 5, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or…